linjc16/ctgov huggingface dataset:
The Learning and Memory of the Experience of Pain

Study Overview
=================
Brief Summary
-----------------
This study investigates the learning and memory of pain.

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Behavioral: Learning and Memory of Pain


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female healthy volunteers. 18-65 years of age. Right-handed. Fluency in English. Ability to read and understand English; English can be a second language provided that the participant feels that he/she is able to understand all the questions used in the assessment measures. Exclusion Criteria: Any previous experience with conditioned analgesia/hyperalgesia paradigms. Presence of any illness or medication use that is judged to interfere with the trial. For example: psychiatric disorder according to the DSM-IV manual, medication that can influence cognition or emotional processing, i.e. sleep medication, antidepressants, anti-convulsants or opioids. Unwillingness to receive brief pain stimulation administered by a heat probe on the hand. Instability of responses to experimental heat pain Any contraindications to fMRI scanning for subjects in Experiment 2 (including metal implants, claustrophobia, history of head trauma, and pregnancy). Peripheral neuropathy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Learning and Memory of Pain|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Myocardial Contrast Echocardiography in Congenital Heart Disease

Study Overview
=================
Brief Summary
-----------------
Patients with congenital heart disease in whom the right ventricle is exposed to pressure or volume overload show progressive systolic dysfunction of the right ventricle, the fact of which conveys substantial morbidity and mortality. The aim of this study is to investigate the myocardial perfusion in these patients by myocardial contrast echocardiography (MCE) in order to determine whether disturbed blood flow plays a role in the development of right ventricular systolic dysfunction.

Official Title
-----------------
Quantification of the Myocardial Microcirculation by Contrast Echocardiography In Adult Patients With Congenital Heart Disease

Conditions
-----------------
D-Transposition of Great Arteries, Tetralogy of Fallot

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: D-TGA or Fallot-Tetralogy or Healthy person written informed consent Age >= 18 years Exclusion Criteria: Anaemia Pregnancy and breast feeding Diabetes mellitus Contraindications to stress testing (ergometry or adenosine) Known adverse reaction or hypersensitivity against V08DA (SonoVue) or its components or against adenosine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TGA group<br>The TGA group consists of 15 patients treated withMustard or Senning procedures for surgical repaired of D-TGA atrial switch operation. | |
| TOF group<br>The TOF group consists of 15 patients with surgically corrected TOF. | |
| Control group<br>The control group C consists of 15 control subjects (AH) with normal Doppler Echocardiographic echocardiographic examinations. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Immunologic and Genetic Characteristics of Monoclonal Immunoglobulins in Patient With Tuberculosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the monoclonal protein in patients with tuberculosis and monoclonal gammopathy has anti-tuberculous activity, and whether genes coding their monoclonal proteins show characteristic mutations.

Detailed Description
-----------------
Monoclonal immunoglobulins arise from abnormal proliferation of a single clone of plasma cells. They are composed of a single light and/or heavy chain class, in contrast to polyclonal immunoglobulins. They may occur in malignant lymphoproliferative diseases, such as multiple myeloma, Waldenstrom's macroglobulinemia, lymphoma, chronic lymphocytic leukemia, amyloidosis, or more benign conditions such as monoclonal gammopathy of undetermined significance (MGUS). Recently we have observed monoclonal gammopathy occurring in patients with tuberculosis. Whether tuberculous infection plays a role in the production of monoclonal protein, and whether the monoclonal immunoglobulins possess anti-tuberculous activity are unknown. In the current project we plan to study: (1) whether the monoclonal immunoglobulin developed in patients with tuberculosis reacts with tuberculous antigen (using ELISA), and (2) whether the VH gene sequence analysis of such patient shows different mutation patterns (indicating the presence of intraclonal mutation variation) or not. If there is no intraclonal mutation variation, it suggests that the plasma cell clone is not under current exposure to the mutator, and the production of monoclonal gammopathy is probably not related to tuberculous infection. If, however, the VH gene sequence analysis shows the presence of intraclonal mutation variation, it indicates that the plasma cell clone is continuously under the influence of the mutator. In such case the production of monoclonal protein may be related to tuberculous infection.

Conditions
-----------------
Monoclonal Gammopathy, Tuberculosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Monoclonal Gammopathy with Tuberculosis Exclusion Criteria: No

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy

Study Overview
=================
Brief Summary
-----------------
The purposes of this study are to determine: - whether standard or higher doses of pemetrexed should be given to patients with ovarian or primary peritoneal cancer that has recurred; - the safety and side effects of standard and higher doses of pemetrexed given to patients with ovarian or primary peritoneal cancer that has recurred; - whether standard or higher doses of pemetrexed can help patients with ovarian or primary peritoneal cancer that has recurred.

Official Title
-----------------
A Randomized, Double-Blind Phase 2 Study of Two Doses of Pemetrexed in the Treatment of Platinum-Resistant, Epithelial Ovarian or Primary Peritoneal Cancer

Conditions
-----------------
Ovarian Neoplasms, Primary Peritoneal Cancer

Intervention / Treatment
-----------------
* Drug: Pemetrexed


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient must have been diagnosed with ovarian or primary peritoneal cancer Patient must have had 1 or 2 prior platinum-based chemotherapeutic regimens. Patient must have adequate health status. Patient compliance and geographic proximity that allow for adequate follow up is required. Signed informed consent from the patient or legal representative is required. Exclusion Criteria: Patient is pregnant or breast-feeding Patient has received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. Patient has previously participated in another study investigating pemetrexed. Patient is unable or unwilling to take folic acid, vitamin B12 supplementation, and corticosteroids. Patient cannot be taking nonsteroidal anti-inflammatory drugs around the time of administration of study drug.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Pemetrexed|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the anti-tumor activity, as measured by tumor response rate (proportion of patients with complete or partial response, of 500 mg/m2 vs. 900 mg/m2 of pemetrexed therapy administered every 21 days |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to response |  |  | 
| Duration of response |  |  | 
| Time to objective progressive disease (TtPD) |  |  | 
| Time to treatment failure (TtTF) |  |  | 
| Objective PFS |  |  | 
| OS |  |  | 
| To assess safety and toxicity profile of two doses of pemetrexed in patients with ovarian cancer |  |  |
Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis

Study Overview
=================
Brief Summary
-----------------
The main purpose of this study is to observe the clinical effect of intrathecal administration of liposomal amphotericin B in Cryptococcal Meningitis without Acquired Immune Deficiency Syndrome (AIDS).

Official Title
-----------------
Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome

Conditions
-----------------
Cryptococcal Meningitis

Intervention / Treatment
-----------------
* Drug: Liposomal amphotericin B


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cryptococcus neoformans are found in CSF Exclusion Criteria: Patients with serious heart, lung, liver and renal insufficiency. Patients who took broad-spectrum antibiotics and corticosteroids for a long-term. Patients with AIDS or obvious immunodeficiency. Patients with long term dialysis or intravenous catheter. Patients with other brain organic disease such as purulent meningitis, intracranial swelling, etc.

Ages Eligible for Study
-----------------
Minimum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intrathecal administration group<br> | Drug: Liposomal amphotericin B<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| laboratory examination of cerebrospinal fluid | It includes routine test，biochemistry indicators and cytology ，namely white blood cell count per litre， protein（in g/l），glucose（in mmol/l）and chloride（in mmol/l）in cerebrospinal fluid ，an assessment will be assessed every week | 2 to 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes of clinical symptoms | headache duration, duration of fever,presence of cranial nerve damage | 2 to 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intrathecal administration, Liposomal amphotericin B, Without Acquired Immune Deficiency Syndrome
FST-100 in the Treatment of Acute Adenoviral Conjunctivitis

Study Overview
=================
Brief Summary
-----------------
This randomized, double masked, multi-center study is being conducted to support the safety and efficacy of FST-100 for the treatment of acute adenoviral conjunctivitis.

Official Title
-----------------
A Proof-of-Concept, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of FST-100 Ophthalmic Suspension in the Treatment of Acute Adenoviral Conjunctivitis

Conditions
-----------------
Acute Adenoviral Conjunctivitis

Intervention / Treatment
-----------------
* Drug: FST-100
* Drug: FST-100 (Component #1)
* Drug: FST-100 Vehicle


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have a clinical diagnosis of suspected acute adenoviral conjunctivitis in at least one eye. Exclusion Criteria: Have a known sensitivity to any of the components of FST-100 or FST-100 vehicle.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: FST-100<br> | Drug: FST-100<br>* 0.1% dexamethasone and 0.6% polyvinylpyrrolidone iodine (PVP-Iodine)<br>|
| Experimental: FST-100 (Component #1)<br> | Drug: FST-100 (Component #1)<br>* 0.6% PVP-Iodine ophthalmic solution alone<br>|
| Placebo Comparator: FST-100 Vehicle<br> | Drug: FST-100 Vehicle<br>* FST-100 Vehicle<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adenoviral eradication and clinical resolution of the infection |  | 6-7 days |
Evaluation of the Retina of Subjects Without Diabetes Mellitus and Subjects With Diabetes Mellitus Without Diabetic Retinopathy Using Optical Coherence Tomography

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate topographic features of the posterior pole of the eye in normal subjects as well as in subjects with diabetes mellitus but without diabetic retinopathy (DR) using optical coherence tomography (OCT). The investigators proposal is a novel study to determine retinal volume of normal and diabetic subjects without DR. Specifically, the investigators will establish a standardized reference range for retinal thickness and volume that will provide standards for OCT analysis of different clinical trials for retinal diseases.

Official Title
-----------------
Evaluation of the Retina of Subjects Without Diabetes Mellitus and Subjects With Diabetes Mellitus Without Diabetic Retinopathy Using Optical Coherence Tomography

Conditions
-----------------
Diabetic Retinopathy

Intervention / Treatment
-----------------
* Other: OCT Imaging both Normal and diabetic groups


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy retinas Willingness to sign informed consent to have OCT images taken. Exclusion Criteria: No macular pathology No Diabetes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1: Non Diabetic<br>Normal retina | Other: OCT Imaging both Normal and diabetic groups<br>* Images taken to determine thickness values in the retina<br>* Other names: Ocular Coherence tomography;|
| Group 2: Diabetes with no retinopathy<br>Diabetic patients without diabetic retinopathy | Other: OCT Imaging both Normal and diabetic groups<br>* Images taken to determine thickness values in the retina<br>* Other names: Ocular Coherence tomography;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Normative retinal thickness data for comparison | Normative retinal thickness data for comparison | one year |
Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

Study Overview
=================
Brief Summary
-----------------
This is a 3-month non-interventional, observational study on patients with moderate and severe asthma.

Official Title
-----------------
Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Symbicort


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with moderate and severe asthma on Symbicort SMART treatment Exclusion Criteria: Under 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Symbicort|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate & describe asthma control in adult patients w/moderate to severe asthma treated w/Symbicort SMART following the frequency, type & severity of symptoms through the Asthma Control Questionnaire. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to evaluate the safety of Symbicort SMART treatment through the number and type of reported adverse events 2. assessment of patient's satisfaction with the treatment 3.assessment of physician's satisfaction with the treatment |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma
The Effect of Transcutaneous Electrical Nerve Stimulation (TENS) in Multiple Sclerosis

Study Overview
=================
Brief Summary
-----------------
In this study the researchers want to investigate the effects of long-term transcutaneous electrical nerve stimulation on the cortical excitability of persons with multiple sclerosis.

Conditions
-----------------
Multiple Sclerosis

Intervention / Treatment
-----------------
* Device: Transcutaneous electrical nerve stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Expanded Disability Status Scale (EDSS) scores between 2 and 6.5 Stable MS (no relapse during the last 3 months before study onset) sensory impairment age: between 18 and 68 years old Exclusion Criteria: - Patients with other pathologies associated with peripheral and/or central sensory dysfunction or under psychotropic or antiepileptic medication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 68 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TENS<br>Transcutaneous electrical nerve stimulation will be applied on the impaired hand | Device: Transcutaneous electrical nerve stimulation<br>* 3 weeks, 5 times a week, 60 minutes a day.<br>|
| Sham Comparator: Sham TENS<br>Sham TENS will be applied to the impaired hand | Device: Transcutaneous electrical nerve stimulation<br>* 3 weeks, 5 times a week, 60 minutes a day.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in cortical excitability | Cortical excitability will be assessed using transcranial magnetic stimulation (TMS) | Baseline, immediately after and 3 weeks after the intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Multiple Sclerosis, Transcutaneous electrical nerve stimulation, Cortical Excitability
Electromyography in Thoracic Outlet Syndrome

Study Overview
=================
Brief Summary
-----------------
Record the ENMG data carried out systematically in patients treated by rehabilitation for thoracic outlet syndrome in order to assess their characteristics and judge the relevance of these data in the context of the diagnosis and their possible modifications following the rehabilitation treatment.

Official Title
-----------------
Interest of Electroneuromyography in the Diagnosis of Thoracic Outlet Syndrome

Conditions
-----------------
Thoracic Outlet Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Inpatient rehabilitation for thoracic outlet syndrome Patients' agreement Exclusion Criteria: < 18 years old Not able to consent Pregnancy Musculoskeletal disorders of the upper limbs Acute cardiac, pulmonary, metabolic or neurological diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Trial population<br>No Intervention but evaluation of the electroneuromyography at the M1 visit for patients with a clinical diagnostic of thoracic outlet syndrome. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the presence of ENMG abnormality and in particular on the medial cutaneous nerve of the forearm of patients with a clinical diagnosis of TOS | Conduction abnormality of the medial cutaneous nerve of the forearm | 0 Month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of ENMG changes following rehabilitation treatment of patients | evolution of electrophysiological changes following treatment | 1 Month | 
| Evaluation of ENMG changes following rehabilitation treatment of patients | evolution of the Visual Analog Score for pain (scale from 0 to 10 ; 10 being the worst outcome) | 1 Month | 
| Evaluation of ENMG changes following rehabilitation treatment of patients | evolution of the Quick Disabilities of the Arm, Shoulder and Hand Score (scale from 0 to 100 ; 100 being the worst outcome) | 1 Month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
neurogenic, Thoracic outlet syndrome, electromyography, rehabilitation, diagnosis